Literature DB >> 3058658

The treatment of primary intraocular malignancy.

L W Brady1, A M Markoe, B E Amendola, U L Karlsson, B Micaily, J A Shields, J J Augsburger.   

Abstract

This paper will summarize much of the information derived in an association between The Department of Radiation Oncology of Hahnemann University Hospital and the Oncology Service of Wills Eye Hospital of Thomas Jefferson University, a collaborative effort for the treatment of primary intraocular malignancies that has spanned the last dozen years. In that time we have treated malignant intraocular melanoma by radioactive eyeplaque brachytherapy and have begun to develop a similar program for treatment of recurring retinoblastoma. These experiences will be described.

Entities:  

Mesh:

Year:  1988        PMID: 3058658     DOI: 10.1016/0360-3016(88)90231-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  2 in total

1.  Risk factors for residual and recurrent and metastatic uveal melanoma after trans-scleral local resection.

Authors:  W A Manschot
Journal:  Br J Ophthalmol       Date:  1996-11       Impact factor: 4.638

Review 2.  Uveal melanoma: therapeutic consequences of doubling times and irradiation results; a review.

Authors:  W A Manschot; R van Strik
Journal:  Int Ophthalmol       Date:  1992-03       Impact factor: 2.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.